NCT03890432 is a NA clinical trial of GLUCOSAFE 2 in Critical Illness, sponsored by HEIDEGGER CP.

Who is sponsoring NCT03890432?

NCT03890432 is sponsored by HEIDEGGER CP.

What drugs are being tested in NCT03890432?

Interventions in NCT03890432: GLUCOSAFE 2, Local protocol control group with routine care, Historical control group with routine care.

What condition does NCT03890432 study?

NCT03890432 studies Critical Illness, Energy Supply; Deficiency, Severe, Protein Deficiency, Hypoglycemia, Hyperglycemia.

Is NCT03890432 still recruiting?

NCT03890432 is currently completed. Last updated 12 August 2025.

Last reviewed 2025-08-12 · How we verify

NCT03890432

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GLUCOSAFE 2 - A New Tool for Nutritional Management and Insulin-therapy in the Intensive Care Unit (ICU)

Completed NA Last updated 12 August 2025

What this trial tests

NA trial testing GLUCOSAFE 2 in Critical Illness in 213 participants. Completed in 26 January 2025.

Timeline

10 January 2023

Primary endpoint
26 January 2025

26 January 2025

Quick facts

Lead sponsor	HEIDEGGER CP
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	213
Start date	10 January 2023
Primary completion	26 January 2025
Estimated completion	26 January 2025
Sites	2 locations across Switzerland

Drugs / interventions tested

GLUCOSAFE 2
Local protocol control group with routine care
Historical control group with routine care

Conditions studied

Critical Illness — all drugs for Critical Illness →
Energy Supply; Deficiency, Severe — all drugs for Energy Supply; Deficiency, Severe →
Protein Deficiency — all drugs for Protein Deficiency →
Hypoglycemia — all drugs for Hypoglycemia →

Sponsor

HEIDEGGER CP

Who can join

18 and older, any sex, with Critical Illness or Energy Supply; Deficiency, Severe. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The survival and the outcomes of critically ill patients are strongly influenced by insulin-therapy and nutritional support. The GLUCOSAFE 2 pilot study, aims to test the performance and the security of the new GLUCOSAFE 2 software, developed by the model-based medical decision support of Aalborg University (Denmark) and adapted to the clinical needs in the intensive care unit (ICU) of the Geneva University Hospital (HUG). This new device is based on a mathematical model of the glucose-insulin metabolism and attempts to give advices for better glycaemia control and nutritional therapy. The GLUCOSAFE 2 study hypothesizes that the use of the Glucosafe 2 software will allow better glycaemia ("Time-in-target") control and better achievement of nutritional energy and protein targets in comparison to the local protocols.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Glucosafe 2-A new tool for nutritional management and insulin-therapy in the intensive care unit: Randomized controlled study (the Glucosafe 2 protocol).
de Watteville A, Pielmeier U, Di Marco M, Gayet-Ageron A, et al · · 2025 · PMID 40036206 · DOI 10.1371/journal.pone.0316624

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting

Other HEIDEGGER CP trials

Trials by the same sponsor.

NCT07343440 — Trial on the Impact of Indirect Calorimetry-Guided Nutritional Support on Patient-Centered Outcomes in Critically Ill Pa · NA · not yet recruiting
NCT05865314 — Optimised Nutritional Therapy and Early Physiotherapy in Long Term ICU Patients (NutriPhyT Trial) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03890432 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by HEIDEGGER CP
Last refreshed: 12 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03890432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing